Introduction

The prostate gland is found only in men and produces some of the fluid that makes up semen. The gland is below the bladder. An enlarged prostate and prostate cancer are two separate conditions. An enlarged prostate is a prostate that simply gets bigger as a man ages. Prostate cancer arises from prostate cells that grow uncontrollably. There are several ways of treating prostate cancer. This policy describes when certain drugs may be covered to treat prostate cancer that doesn’t respond to medication or hormone therapy and has spread to other parts of the body.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Note: Initial approval period for drugs listed below will be 3 months. Continued approval beyond the first 3 months will require documentation showing objective response to therapy.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Necessity</th>
</tr>
</thead>
</table>
| **Zytiga® (abiraterone)** | Zytiga® (abiraterone) may be considered medically necessary when used in combination with prednisone for the treatment of patients with:  
• metastatic castrate-resistant prostate cancer (CRPC)  
OR  
• metastatic high-risk castration-sensitive prostate cancer (CSPC) |
| **Yonsa® (abiraterone)** | Yonsa® (abiraterone) may be considered medically necessary when used in combination with methylprednisolone or other corticosteroid for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). |
| **Xtandi® (enzalutamide)** | Xtandi® (enzalutamide) may be considered medically necessary when used:  
• For the treatment of patients with castrate-resistant prostate cancer  
• In combination with androgen deprivation therapy (ADT):  
  o Concurrently receiving a gonadotropin-releasing hormone (GnRH) analog  
  OR  
  o Having had bilateral orchietomy |
| **Erleada™ (apalutamide)** | Erleada™ (apalutamide) may be considered medically necessary for the treatment of patients with non-metastatic castration-resistant prostate cancer. |

Coding

N/A

Related Information
Benefit Application

This policy is managed through the Pharmacy benefit.

Evidence Review

Description

Prostate cancer is a neoplastic disease of the prostate gland. Prostate cancer arises from mutations in cells of the prostate that cause overexpression of enzymes that support androgen biosynthesis, loss of regulation of cell death within the tumor cells, and up regulation of androgen receptors. Androgen receptor binding by androgens plays a crucial role in prostate cancer progression. Most prostate cancers respond to androgen deprivation.

Approximately 60% of all cases of prostate cancer are diagnosed in men 65 years of age or older and 97% occur in men 50 and older. CRPC is a term used to describe prostate cancer which has progressed despite local therapy and first-line hormonal therapy assuring castrate levels of testosterone. Prostate cancers typically progress slowly and there is a high rate of survival for disease detected in early stages, but not for advanced disease stages. In the US, the 5-year survival rate is effectively 100% when the disease is local or regional, but this drops to 31% for disease with distant metastases.

Disease Burden

Prostate cancer is the second most common cause of cancer death in American men. In 2013, an estimated 238,590 men are expected to be diagnosed with prostate cancer, and approximately 29,720 are expected to have died from the disease. While it is prevalent, only 15% of all prostate cancer patients develop mCRPC prior to chemotherapy, and just 9% of all prostate cancer patients progress to mCRPC on first-line docetaxel chemotherapy.

The condition is associated with a substantial economic burden, due to high incidence rates and high costs associated with management of advanced cancer stages. The high management cost burden arises from the requirement for hospitalizations, chemotherapy, palliative surgical procedures, and computed tomography (CT) or magnetic resonance imaging (MRI) scans to monitor potential bone metastases. In 2007, per-patient per-month CRPC costs for men over the
age of 40 were approximately $1,800, with ambulatory visits ($1,152) and inpatient stays ($559)
comprising the majority of these costs. Total all-cause healthcare costs for these same patients
totaled $3,500 per-patient per-month.

Rationale

Treatment Alternatives

Several approved pharmacotherapeutic alternatives for mCRPC have demonstrated some
benefit in estimated survival compared with acceptable controls.

Zytiga® (abiraterone) + prednisone

Zytiga® (abiraterone) acetate is an oral drug that is converted in vivo to abiraterone a CYP17
complex (17α-hydroxylase/C17,20-lyase) inhibitor that interrupts androgen biosynthesis
throughout the body (testes, adrenal gland, and prostate tumor). Prostate cancer is very often
an androgen-driven disease. CYP17 inhibition may also lead to increased mineralocorticoid
production by the adrenal gland secondary to increased adrenocorticotropic hormone (ACTH)
production from a feedback mechanism induced by low cortisol levels. Up regulated ACTH leads
to increased deoxycorticosterone which exhibits mineralocorticoid activity. Results from clinical
trials have shown that coadministration of a corticosteroid (eg, prednisone) with abiraterone
reduces the incidence and severity of mineralocorticoid excess associated adverse reactions. An
RCT showed that abiraterone and prednisone improved radiographic progression-free survival,
time to initiation of chemotherapy, time to onset or worsening of pain, and time to deterioration
in improvement status.

Xtandi® (enzalutamide)

Xtandi® (enzalutamide) is indicated for the treatment of mCRPC in patients who have received
prior chemotherapy containing docetaxel. One well-designed RCT has shown enzalutamide
prolongs overall survival (OS) by 4.8 months, time to prostate-specific antigen (PSA) progression
(TTPP), radiographic progression-free survival (rPFS), and time to first skeletal-related event
(SRE) compared with placebo. There is currently no direct evidence with which to assess real
world comparative effectiveness. Indirect evidence suggests a similar modest (2-5 month)
increase in overall survival and hazard for risk of death with enzalutamide, abiraterone, or
cabazitaxel in patients with mCRPC previously treated with a docetaxel-based regimen. However, it is important to note that the abiraterone and cabazitaxel studies had control arms which included agents with anti-tumor activity (prednisone and mitoxantrone + prednisone, respectively) compared to placebo control for enzalutamide. Evidence of safety is currently limited. The most significant toxicity reported for Xtandi® (enzalutamide) is seizure, although this occurs rarely (incidence about 1%).

Indirect evidence suggests favorable safety and tolerability compared to other second-line treatments with survival benefit for mCRPC. Enzalutamide lacks the detrimental effects of mineralocorticoid excess induced by Jevtana® (cabazitaxel), and thus does not require co-administration with corticosteroids, which may complicate CRPC treatment. Unlike Jevtana® (cabazitaxel), Xtandi® (enzalutamide) is not reported to commonly cause neuropathy or severe myelosuppression, two significant toxicities which can lead to morbidity and limit additional therapy in this patient population.

**Guideline Recommendations**

The latest prostate cancer guidelines from the NCCN recommend the following systemic therapies for advanced disease (primarily category 2a unless otherwise labeled):

**Metastatic castration-recurrent prostate cancer**

**Asymptomatic visceral disease:** Sipuleucel-T or secondary hormone therapy (including abiraterone or enzalutamide) or docetaxel or clinical trial

**Bone metastases:** Denosumab(1) or zoledronic acid(1)

**Disease recurrence post-abiraterone or enzalutamide or intolerance:** Docetaxel (1) or abiraterone or enzalutamide or Radium-223 for symptomatic bone metastases (1) or Sipuleucel-T* or other secondary hormone therapy or clinical trial.

**Disease recurrence post-docetaxel or first-line therapy intolerance:** Abiraterone (1, post-docetaxel) or enzalutamide (1, post-docetaxel) or cabazitaxel (1, post-docetaxel) or salvage chemotherapy or docetaxel rechallenge or mitoxantrone or other secondary hormone therapy or Provenge® (sipuleucel-T) * or clinical trial

*Note: Provenge® (sipuleucel-T) is recommended only for asymptomatic or minimally symptomatic patients with an ECOG performance status of 0-1. It is not indicated for patients with hepatic metastases or life expectancy <6 months.

**General:** Maintain castrate serum testosterone levels
Symptomatic visceral disease:Docetaxel or mitoxantrone (for patients not candidates for docetaxel) or abiraterone or enzalutamide or palliative care for symptomatic bone metastases or clinical trial

These guidelines are generally aligned with evidence-based European guidelines, excepting the adoption of use of Xtandi® (enzalutamide).

Non-Metastatic castration-resistant prostate cancer

NCCN guidelines recommend apalutamide, especially if PSA doubling time is < 10 months. Additionally, bone support should be used in patients receiving this medication (fracture 11% vs 6.5% placebo).

National Comprehensive Cancer Network (NCCN) Compendium

The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium is based directly on the NCCN Clinical Practice Guidelines in Oncology. The compendium lists specific panel recommendations for off-label uses of drugs, and each recommendation is supported by a level of evidence category.

The NCCN Categories of Evidence and Consensus used in the recommendations are:

- Category 1: The recommendation is based on high level evidence (eg, randomized controlled trials) and there is uniform NCCN consensus.
- Category 2A: The recommendation is based on lower level evidence and there is uniform NCCN consensus.
- Category 2B: The recommendation is based on lower level evidence and there is nonuniform NCCN consensus (but no major disagreement).
- Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
2014 Update

A search of the literature from 7/1/13 to 10/31/14 did not identify new evidence requiring changes to this policy.

2015 Update

Updated new indications and NCCN recommendations for Xtandi® (enzalutamide). A search of the literature from 7/1/14 to 8/31/15 did not identify new evidence requiring changes to this policy.

2016 Update

Updated policy based on new NCCN recommendations. Zytiga® (abiraterone acetate) step removed for Xtandi® (enzalutamide).

2018 Update

Updated new product labeling and NCCN recommendations which now include Erleada™. A search of the literature from 4/11/2017 to 3/13/2018 did not identify new evidence requiring changes to this policy. Yonsa® (abiraterone) criteria was added.

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/09/13</td>
<td>New policy effective May 1, 2013. Add to Prescription Drug Section. Enzalutamide (Xtandi®) is approved for the treatment of prostate cancer when conditions are met.</td>
</tr>
<tr>
<td>07/08/13</td>
<td>Minor Update – Clarification was added to the policy that it is managed through the member’s pharmacy benefit; this is now listed in the header and within the coding section.</td>
</tr>
<tr>
<td>12/04/13</td>
<td>Replace policy. Policy section updated with the addition of abiraterone (Zytiga®), considered medically necessary for treating castration-resistant prostate cancer in combination with prednisone. (This was previously addressed in policy 5.01.540.) Rationale section updated in support of this addition.</td>
</tr>
<tr>
<td>12/08/14</td>
<td>Annual review. Policy updated with literature review; no change in policy statements</td>
</tr>
<tr>
<td>10/13/15</td>
<td>Annual Review. Updated enzalutamide (Xtandi®) for new indications.</td>
</tr>
<tr>
<td>12/08/15</td>
<td>Interim Update. Medical necessity coverage criteria for enzalutamide (Xtandi®) expanded.</td>
</tr>
<tr>
<td>10/25/16</td>
<td>Minor formatting update. Added second level bullet, Policy section under</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>01/01/17</td>
<td>Enzalutamide (Xtandi®) criteria. Annual Review, changes approved December 13, 2016. Updated enzalutamide and abiraterone acetate for new indications. Medical necessity coverage criteria updated (Zytiga® step removed).</td>
</tr>
<tr>
<td>05/01/17</td>
<td>Annual Review, changes approved April 11, 2017. A statement outlining the length of therapy for initial and subsequent approval has been added to the policy.</td>
</tr>
<tr>
<td>03/01/18</td>
<td>Interim Review, approved February 27, 2018. Added FDA approved Erleada to policy. Zytiga criteria was revised to include new FDA label update.</td>
</tr>
<tr>
<td>07/01/18</td>
<td>Annual Review, approved June 22, 2018. Literature review 04/11/2017 to 3/13/2018. NCCN guidelines updated. Yonsa® (abiraterone) criteria was added to policy.</td>
</tr>
<tr>
<td>11/01/18</td>
<td>Interim Review, approved October 26, 2018. Updated Yonsa indication to allow any corticosteroid. Updated Xtandi indication per label.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a customer service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination Is Against the Law

LifeWise Health Plan of Oregon complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

LifeWise:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-6396, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@LifeWiseHealth.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.


Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through LifeWise Health Plan of Oregon. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-596-3440 (TTY: 800-842-5357).

Français (French):

Deutsche (German):

Italiano (Italian):

String (Chinese):
本通知有重要的訊息。本通知可能有關於您透過 LifeWise Health Plan of Oregon 提交的申請或保單的重要訊息。本通知內可能有重要日期。您可能需要在截止日期之前採取行動，以保留您的健康保險或費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-596-3440 (TTY: 800-842-5357).

Oromo (Cushite):

Ilokano (Ilocano):

037405 (07-2016)
This notice contains important information. This notice may contain information about your claim or coverage that may affect your care. You may have the right to request a copy of this notice in any language of your choice. Please contact your insurance provider for more information.

800-596-3440 (TTY: 800-842-5357)